PubMed

Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes.

Tan MH, Baksi A, Krahulec B, Kubalski P, Stankiewicz A, Urquhart R, Edwards G, Johns D; GLAL Study Group.

Diabetes Care. 2005 Mar;28(3):544-50.PMID: 15735185 [PubMed - indexed for MEDLINE]Related articlesFree article

Effects of pioglitazone and glimepiride on glycemic control and insulin sensitivity in Mexican patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, parallel-group trial.

Tan M, Johns D, González Gálvez G, Antúnez O, Fabián G, Flores-Lozano F, Zúñiga Guajardo S, Garza E, Morales H, Konkoy C, Herz M; GLAD Study Group.

Clin Ther. 2004 May;26(5):680-93.PMID: 15220012 [PubMed - indexed for MEDLINE]Related articles

Comparison of glycaemic control over 1 year with pioglitazone or gliclazide in patients with Type 2 diabetes.

Perriello G, Pampanelli S, Di Pietro C, Brunetti P; Italian Pioglitazone Study Group.

Diabet Med. 2006 Mar;23(3):246-52.PMID: 16492206 [PubMed - indexed for MEDLINE]Related articles

Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.

Derosa G, Cicero AF, D'Angelo A, Gaddi A, Ciccarelli L, Piccinni MN, Salvadeo SA, Pricolo F, Ferrari I, Gravina A, Ragonesi PD.

Clin Ther. 2006 May;28(5):679-88. Erratum in: Clin Ther. 2006 Sep;28(9):1483. PMID: 16861090 [PubMed - indexed for MEDLINE]Related articles

Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.

Rosenstock J, Brazg R, Andryuk PJ, Lu K, Stein P; Sitagliptin Study 019 Group.

Clin Ther. 2006 Oct;28(10):1556-68.PMID: 17157112 [PubMed - indexed for MEDLINE]Related articles

A long-term comparison of pioglitazone and gliclazide in patients with Type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trial.

Charbonnel BH, Matthews DR, Schernthaner G, Hanefeld M, Brunetti P; QUARTET Study Group.

Diabet Med. 2005 Apr;22(4):399-405.PMID: 15787663 [PubMed - indexed for MEDLINE]Related articles

Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes.

Charbonnel B, Schernthaner G, Brunetti P, Matthews DR, Urquhart R, Tan MH, Hanefeld M.

Diabetologia. 2005 Jun;48(6):1093-104. Epub 2005 May 12.PMID: 15889234 [PubMed - indexed for MEDLINE]Related articles

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.

Moretto TJ, Milton DR, Ridge TD, Macconell LA, Okerson T, Wolka AM, Brodows RG.

Clin Ther. 2008 Aug;30(8):1448-60. Erratum in: Clin Ther. 2008 Oct;30(10):1937. PMID: 18803987 [PubMed - indexed for MEDLINE]Related articles

Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.

Mattoo V, Eckland D, Widel M, Duran S, Fajardo C, Strand J, Knight D, Grossman L, Oakley D, Tan M; H6E-MC-GLAT study group.

Clin Ther. 2005 May;27(5):554-67.PMID: 15978304 [PubMed - indexed for MEDLINE]Related articles

Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.

Roberts VL, Stewart J, Issa M, Lake B, Melis R.

Clin Ther. 2005 Oct;27(10):1535-47.PMID: 16330290 [PubMed - indexed for MEDLINE]Related articles

Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.

Lawrence JM, Reid J, Taylor GJ, Stirling C, Reckless JP.

Diabetes Care. 2004 Jan;27(1):41-6.PMID: 14693964 [PubMed - indexed for MEDLINE]Related articlesFree article

Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes.

Yanagawa T, Araki A, Sasamoto K, Shirabe S, Yamanouchi T.

Metabolism. 2004 Mar;53(3):353-7.PMID: 15015149 [PubMed - indexed for MEDLINE]Related articles

Rosiglitazone/metformin fixed-dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24-week, multicenter, randomized, double-blind, parallel-group study.

Bailey CJ, Bagdonas A, Rubes J, McMorn SO, Donaldson J, Biswas N, Stewart MW.

Clin Ther. 2005 Oct;27(10):1548-61.PMID: 16330291 [PubMed - indexed for MEDLINE]Related articles

Glycemic control and treatment failure with pioglitazone versus glibenclamide in type 2 diabetes mellitus: a 42-month, open-label, observational, primary care study.

Hanefeld M, Pfützner A, Forst T, Lübben G.

Curr Med Res Opin. 2006 Jun;22(6):1211-5.PMID: 16846554 [PubMed - indexed for MEDLINE]Related articles

Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.

Charbonnel B, Roden M, Urquhart R, Mariz S, Johns D, Mihm M, Widel M, Tan M.

Diabetologia. 2005 Mar;48(3):553-60. Epub 2005 Mar 1.PMID: 15739120 [PubMed - indexed for MEDLINE]Related articles

Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.

Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF.

J Clin Pharm Ther. 2006 Aug;31(4):375-83.PMID: 16882108 [PubMed - indexed for MEDLINE]Related articles

Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.

Betteridge DJ, Vergès B.

Diabetologia. 2005 Dec;48(12):2477-81. Epub 2005 Nov 10.PMID: 16283239 [PubMed - indexed for MEDLINE]Related articles

2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes.

Seufert J, Urquhart R.

Diabetes Res Clin Pract. 2008 Mar;79(3):453-60. Epub 2007 Dec 26.PMID: 18160120 [PubMed - indexed for MEDLINE]Related articles

Safety and tolerability of pioglitazone, metformin, and gliclazide in the treatment of type 2 diabetes.

Belcher G, Lambert C, Edwards G, Urquhart R, Matthews DR.

Diabetes Res Clin Pract. 2005 Oct;70(1):53-62.PMID: 16002175 [PubMed - indexed for MEDLINE]Related articles

Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study.

Lewin A, Lipetz R, Wu J, Schwartz S.

Clin Ther. 2007 May;29(5):844-55.PMID: 17697903 [PubMed - indexed for MEDLINE]Related articles